iso2LUMC0146iKLHL10
LUMCi046-A-1
General
Cell Line |
|
| hPSCreg name | LUMCi046-A-1 |
| Cite as: | LUMCi046-A-1 (RRID:CVCL_A7RZ) |
| Alternative name(s) |
iso2LUMC0146iKLHL10
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
LUMCi046-A (LUMC0146iKLHL10) Donor diseases: Intermediate epidermolysis bullosa simplex with cardiomyopathy LUMCi045-A (LUMC0145iKLHL01) Donor diseases: Intermediate epidermolysis bullosa simplex with cardiomyopathy LUMCi045-A-1 (iso01LUMC0145iKLHL01) Donor diseases: Intermediate epidermolysis bullosa simplex with cardiomyopathy |
| Last update | 3rd May 2021 |
| User feedback | |
Provider |
|
| Generator |
Leiden University Medical Center (LUMC)
Contact:
LUMC hiPSC core facility |
| Owner | LUMC hiPSC core facility |
| Distributors | |
| Derivation country | Netherlands |
External Databases |
|
| BioSamples | SAMEA8868396 |
| Cellosaurus | CVCL_A7RZ |
| Wikidata | Q107115884 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Additional restrictions:
under MTA request addressed to Karine Raymond |
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Hispanic, Chilean |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | patient 15 in Schwieger-Briel et al., 2018 (10.1016/j.jid.2018.07.022) |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA8868392 |
Ethics
Also have a look at the ethics information for the parental line
LUMCi046-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Integrated DNA Technologies (IDT) |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
LUMCi046-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Vitronectin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
TeSR™ E8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| alpha fetoprotein (AFP) |
Yes |
In vitro directed differentiation
| Marker | Expressed |
| beta-III tubulin |
Yes |
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY[20]
Passage number: 28
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.